Growth in congenital adrenal hyperplasia

Indian Journal of Pediatrics

Volumn 73, Issue 1, 2006, Pages 89-93

  Nguyen, An T T ^a   Brown, Justin J ^b   Warne, Garry L ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Congenital adrenal hyperplasia; Height; Obesity

Indexed keywords

ANDROSTENEDIONE; CORTISONE ACETATE; DEXAMETHASONE; FLUDROCORTISONE; FLUTAMIDE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; SODIUM CHLORIDE; TESTOLACTONE; TESTOSTERONE;

ACNE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL SUPPRESSION; BODY HEIGHT; BODY MASS; BONE AGE; CLINICAL TRIAL; CONFERENCE PAPER; CONGENITAL ADRENAL HYPERPLASIA; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GROWTH ACCELERATION; GROWTH HORMONE DEFICIENCY; GROWTH INHIBITION; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; MALE; MEDICAL LITERATURE; META ANALYSIS; OBESITY; PATIENT COMPLIANCE; PUBLICATION; SALT LOSING NEPHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHILD; DRUG EFFECT; GROWTH; GROWTH DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; REVIEW;

ADRENAL HYPERPLASIA, CONGENITAL; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; GROWTH; GROWTH DISORDERS; HUMANS; MALE;

EID: 33745958009     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02758268     Document Type: Conference Paper

References (38)

1. Eugster EA et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis.[see comment]. Journal of Pediatrics 2001. 138(1): 26-32.
2. Manoli I et al Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clinical Endocrinology 2002; 57(5): 669-676.
3. New MI et al. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Journal of Endocrinological Investigation 1989. 12(8 Suppl 3): 91-95.
4. Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics , 2000; 106(4) : 767-773.
5. Klingensmith GJ et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatrics 1977; 90(6) : 996-1004.
6. Jaaskelainen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatric Research 1997; 41(1): 30-33.
7. Weintrob N et al. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height. European J Endocrinology 1997; 136(2): 188-195.
8. Thilen A et al. Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency.[see comment]. Acta Paediatrica 1995; 84(8): 894-898.
9. Rasat R, Espiner EA, Abbott GD, Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. New Zealand Medical Journal 1995; 108(1005): 311-314.
10. Muirhead S et al. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatrics 2002; 141(2): 247-252.
11. Brook CG et al. Height correlations between parents and mature offspring in normal subjects and in subjects with Turner's and Klinefelter's and other syndromes. Annals of Human Biology 1977; 4 (1) : 17-22.
12. Gussinye, M et al. Adult height, pattern of growth and pubertal development in patients with congenital adrenal hyperplasia, salt losing form]. Medicina Clinica 1997. 108(3): 87-90.
13. Yu, A.C. and D.B. Grant, Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood. Acta Paediatrica 1995; 84(8): 899-903.
14. Knorr, D. and S.G. Hinrichsen de Lienau, Persistent obesity and short final height after corticoid overtreatment for congenital adrenal hyperplasia (CAH) in infancy. Acta Paediatrica Japonica 1988. 30 (Suppl): 89-92.
15. Speiser PW, White PC, Congenital adrenal hyperplasia. New England Journal of Medicine 2003; 349(8): 776-88.
16. Gmyrek GA et al . Bilateral laparoscopic adrenalectomy as a treatment for classic congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency. Pediatrics 2002; 109(2): E28.
17. Warinner SA et al. Study of three patients with congenital adrenal hyperplasia treated by bilateral adrenalectomy. World Journal of Surgery 2000; 24(11): 1347-1352.
18. Scaroni C et al. Unilateral adrenal tumor, erectile dysfunction and infertility in a patient with 21-hydroxylase deficiency: effects of glucocorticoid treatment and surgery. Experimental and Clinical Endocrinology & Diabetes 2003; 111(1): 41-43.
19. Kerrigan JR et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. Journal of Clinical Endocrinology & Metabolism 1993; 76(6): 1505-1510.
20. Linder BL et al. Cortisol production rate in childhood and adolescence. [see comment]. Journal of Pediatrics 1990. 117(6): 892-896.
21. Ten S, New M, Maclaren N, Clinical review 130: Addison's disease 2001. J Clinical Endocrinology & Metabolism 2001; 86(7): 2909-2922.
22. Silva IN et al. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood 1997; 77(3): 214-218.
23. Stikkelbroeck NM et al. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre) puberty. Journal of Clinical Endocrinology & Metabolism 2003; 88(8): 3525-3530.
24. Ciaccio M et al. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia. Medicina 2002; 62(6): 551-554.
25. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia.[see comment]. Journal of Clinical Endocrinology and Metabolism 1997; 82(12): 3926-3929.
26. Kirkland RT et al . The effect of therapy on mature height in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1978; 47(6): 1320-1324.
27. Horrocks PM, London DR. A comparison of three glucocorticoid suppressive regimes in adults with congenital adrenal hyperplasia. Clinical Endocrinology 1982. 17(6): p. 547-556.
28. Young MC, Hughes IA. Dexamethasone treatment for congenital adrenal hyperplasia. Archives of Disease in Childhood 1990. 65(3): 312-314.
29. Balsamo A et al. [Corticosteroid treatment regimes and growth hormone secretion in congenital adrenogenital syndrome]. Pediatria Medica Chirurgica 1993; 15(6): 585-587.
30. David M et al. [Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency]. Archives de Pediatrie 1994; 1(4): 363-367.
31. Brook CG et al . Experience with long-term therapy in congenital adrenal hyperplasia. Journal of Pediatrics 1974; 85(1): 12-19.
32. Young MC, Ribeiro J, Hughes IA. Growth and body proportions in congenital adrenal hyperplasia. Archives of Disease in Childhood 1989; 64(11): 1554-1558.
33. Clayton, G.W., Patterns of growth from birth to maturity in infants and children with congenital adrenal hyperplasia. Acta Endocrinologica. Supplementum 1986; 279: 295-304.
34. Li, HY, Dahir KM, Blevins LS, Jr. Treatment of adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a clinical practice audit. Endocrine Practice 2003; 9(5): 347-352.
35. Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clinical Endocrinology 1987; 27(6) : 635-642.
36. Nanbu A et al. [A clinical study of congenital adrenal hyperplasia]. Hinyokika Kiyo - Acta Urologica Japonica., 1989; 35(11): 1831-1837.
37. Merke DP et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2000; 85(3): 1114-1120.
38. Lopes LA et al. Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? Journal of Pediatric Endocrinology and Metabolism 1998; 11(6): 733-737.